Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 1, 2010

FDA Clears Allergan’s Lumigan 0.01% Eye Drops for Lowering Intraocular Pressure

  • FDA has approved Allergan’s Lumigan® 0.01% bimatoprost solution as first-line therapy for reducing intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. The once-daily eye-drop product is an optimized reformulation of Lumigan 0.03%. Allergan says the drug will be available during the fourth quarter of 2010.

    A three-month study with Lumigan 0.01% showed that treatment lowered IOP up to 7 mmHg from baseline in patients with an average baseline of 23.5 mmHg, despite using only one-third of the drug concentration in Lumigan 0.03%.

    Allergan’s eyecare pharmaceuticals portfolio made net sales of $2.1 billion in the year to December 31 2010, up about $100,000 on sales in 2008. During May 2010 the firm reported FDA approval of Zymaxid™ 0.5%, a topical fluoroquinolone anti-infective indicated for the treatment of bacterial conjunctivitis. The firm projects to achieve Lumigan franchise product net sales of $490-$510 million  in 2010.

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »